BackMerckInc Overview
Merck & Co Inc

MerckInc Target Price

Analysts' average 12-month price target for MerckInc is $140.

Get informed when a big investor buys or sells

+ Follow

Share Price

$135.97

Average Target Price

$137.691.3% upside

13 analysts in the last 4 months

High: $155 | Low: $105

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-12Daiwa$1435.2% upsideOpen
2026-08-11Argus ResearchJasper Hellweg$1456.6% upsideOpen
2026-08-05Morgan StanleyTerence Flynn$11614.7% downsideOpen
2026-08-05GuggenheimVamil Divan$1467.4% upsideOpen
2026-07-29BarclaysEmily Field$15010.3% upsideOpen
2026-07-27BernsteinCourtney Breen$10522.8% downsideOpen
2026-07-13BMO Capital$1424.4% upsideOpen
2026-07-13GuggenheimVamil Divan$1456.6% upsideOpen
2026-07-06HSBCRajesh Kumar$15010.3% upsideOpen
2026-06-30Jefferies$1413.7% upsideOpen
2026-06-29Scotiabank$15514% upsideOpen
2026-06-02GuggenheimVamil Divan$1403% upsideOpen
2026-05-01Morgan StanleyTerence Flynn$11217.6% downsideOpen
2026-03-12Wells FargoMohit Bansal$15010.3% upsideOpen
2026-02-24RBC CapitalTrung Huynh$1424.4% upsideOpen
2026-02-13Deutsche BankJames Shin$15010.3% upsideOpen
2026-02-04Goldman SachsAsad Haider$1332.2% downsideOpen
2026-02-04BMO Capital$1350.7% downsideOpen
2026-02-04Bernstein$10026.5% downsideOpen
2026-02-03Scotiabank$1360% upsideOpen
2026-01-27Cantor Fitzgerald$11614.7% downsideOpen
2026-01-08Wolfe Research$1350.7% downsideOpen
2026-01-07UBS$1304.4% downsideOpen
2025-12-18BMO Capital$1304.4% downsideOpen
2025-12-12Morgan Stanley$10225% downsideOpen
2025-12-10HSBCRajesh Kumar$12011.7% downsideOpen
2025-12-05Guggenheim$12210.3% downsideOpen
2025-12-04ScotiabankLouise Chen$12011.7% downsideOpen
2025-12-02Goldman SachsAsad Haider$12011.7% downsideOpen
2025-11-03Morgan StanleyTerence Flynn$10026.5% downsideOpen
2025-09-17Berenberg BankLuisa Hector$9033.8% downsideOpen
2025-07-10Morgan StanleyTerence Flynn$9827.9% downsideOpen
2025-04-25BMO CapitalEvan Seigerman$8239.7% downsideOpen
2025-02-05Morgan StanleyTerence Flynn$10622% downsideOpen
2024-12-02BernsteinCourtney Breen$11019.1% downsideOpen
2024-11-15JefferiesAkash Tewari$1488.8% upsideOpen
2024-11-01BMO CapitalEvan David Seigerman$1360% upsideOpen
2024-10-09UBSTrung Huynh$1360% upsideOpen
2024-10-07BarclaysCarter Gould$1403% upsideOpen
2024-08-15JefferiesAkash Tewari$1478.1% upsideOpen
2024-07-31UBSColin Bristow$1424.4% upsideOpen
2024-07-31Bank of America SecuritiesGeoff Meacham$1456.6% upsideOpen
2024-06-12Wells FargoMohit Bansal$1403% upsideOpen
2024-05-30BMO CapitalEvan David Seigerman$1488.8% upsideOpen
2024-03-27Truist Financial$1424.4% upsideOpen
2024-03-27JefferiesAkash Tewari$1456.6% upsideOpen
2024-03-27Wells FargoMohit Bansal$1350.7% downsideOpen
2023-11-22Loop Capital MarketsEvan David Seigerman$1322.9% downsideOpen
2023-04-12OppenheimerJay Olson$1478.1% upsideOpen
2023-02-03Wells Fargo$12011.7% downsideOpen

MerckInc (MRK) FAQ

MerckInc (MRK) currently reports a target price of $140. Use the charts on this page to explore MerckInc's target price history and peer comparisons.

Analysts' average 12-month price target for MerckInc is $140, about 1.3% upside from the current share price of $135.97. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $140, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MerckInc, and consider following MRK for alerts when major investors trade the stock.

MerckInc is classified in the Healthcare sector. On target price, it currently shows $140. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MRK with unrelated industries.